- Main
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
- Peloquin, Charles A;
- Phillips, Patrick PJ;
- Mitnick, Carole D;
- Eisenach, Kathleen;
- Patientia, Ramonde F;
- Lecca, Leonid;
- Gotuzzo, Eduardo;
- Gandhi, Neel R;
- Butler, Donna;
- Diacon, Andreas H;
- Martel, Bruno;
- Santillan, Juan;
- Hunt, Kathleen Robergeau;
- Vargas, Dante;
- von Groote-Bidlingmaier, Florian;
- Seas, Carlos;
- Dianis, Nancy;
- Moreno-Martinez, Antonio;
- Kaur, Pawandeep;
- Horsburgh, C Robert
- et al.
Published Web Location
https://doi.org/10.1128/aac.00770-18Abstract
Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.).
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-